<DOC>
	<DOCNO>NCT00714259</DOCNO>
	<brief_summary>A non-myeloablative treatment strategy uniform selection criterion enable patient variety low grade B-Cell malignancy attain long term disease control without unacceptably high treatment relate mortality .</brief_summary>
	<brief_title>Non-Myeloablative Allogeneic HSCT From HLA Matched Related Unrelated Donors Treatment Low Grade B Cell Malignancies</brief_title>
	<detailed_description>Non myeloablative transplant aim achieve immunological advantage graft versus tumor effect conventional myeloablative therapy without cause high treatment related toxicity . Non myeloablative transplant gain wide acceptance way achieve longer disease free survival patient low grade B-cell malignancy , otherwise incurable disease . Recent study non-myeloablative HSCT demonstrate powerful effect graft versus leukemia alone myeloma malignant B-cell malignancy transplant perform low grade , low volume disease .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<criteria>Stage II III nonprogressive disease Multiple Myeloma . CLL/SLL , low grade Hodgkin Lymphomas good partial response complete response nonprogressive disease . ≤ 70 year old . Eligible willing HLA match related donor . Bilirubin &lt; 2xULN . ALT AST &lt; 3xULN . LVEF &gt; 40 % . Creatinine Clearance &gt; 40mL/min . Pulmonary function DLCO correct ≥ 70 % . Minimum performance score 70 % . Platelet count &gt; 130 x103 micro L. LDH ≤1.5xULN . No proceed comorbid condition significantly increase risk severe regimen related toxicity . No uncontrolled infection . Age &gt; 70 year old . Performance status &lt; 70 % . Uncontrolled infection HIV positive Prior malignancy felt &lt; 80 % probability cure . Pregnant , breastfeeding , refuse use contraceptive technique 12 month follow transplant . Prior Allograft History rapidly grow disease diagnosis progression MDS . No eligible willing HLA match donor .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Low Grade B Cell Malignancies</keyword>
	<keyword>nonmyeloablative transplant</keyword>
	<keyword>allogeneic</keyword>
</DOC>